Global Team Leader
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Daiichi Sankyo
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Global Team Leader as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:54 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05993234 · A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · active not recruiting · HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma · study director
- N/ANCT05945732 · DESTINY Breast Respond HER2-(Ultra)Low EuropeDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · recruiting · Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer · study director
- Ph3NCT03529110 · DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]Daiichi Sankyo · completed · Breast Cancer · study director
- Ph1NCT03523572 · Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerDaiichi Sankyo · completed · Breast Cancer, Urothelial Carcinoma · study director
- Ph3NCT03523585 · DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]Daiichi Sankyo · completed · Breast Cancer · study director
- Ph2NCT03505710 · DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung CancerDaiichi Sankyo · terminated · Non-Small Cell Lung Cancer · study director
- Ph1NCT03401385 · First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)Daiichi Sankyo Co., Ltd. · active not recruiting · Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer · study director
- Ph3NCT02371369 · Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)Daiichi Sankyo · completed · Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor · study director
- Ph1NCT02350712 · Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck CancerDaiichi Sankyo · completed · Squamous Cell Carcinoma of the Head and Neck · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.